IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

A. Padoan, L. Sciacovelli, D. Basso, Davide Negrini, S. Zuin, C. Cosma, D. Faggian, P. Matricardi, M. Plebani

Clinica Chimica Acta, 2020

Abstract Validation studies of serological antibody tests must be properly designed for clinical, epidemiological and Public Health objectives such as confirmation of suspected COVID-19 cases, certification of seroconversion after infection, and epidemiological surveillance. We evaluated the kinetics of IgM, IgA and IgG SARS-CoV-2 antibodies in COVID-19 patients with confirmed (rRT-PCR) infection. We found that the IgA response appears and grows early, peaks at week 3, and it is stronger and more persistent than the IgM response. Further longitudinal investigations of virus-specific antibodies functions and of their protective efficacy over time are needed.

Cited by 111 publications.

Field of study: Medicine

10.1016/j.cca.2020.04.026